Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Ischemia/reperfusion injury: effect of simultaneous inhibition of plasma cascade systems versus specific complement inhibition.

Tytuł:
Ischemia/reperfusion injury: effect of simultaneous inhibition of plasma cascade systems versus specific complement inhibition.
Autorzy:
Duehrkop C; Department of Clinical Research, University of Bern, Murtenstrasse 50, P.O. Box 44, CH-3010 Bern, Switzerland; Graduate School of Cellular and Biomedical Sciences, University of Bern, Switzerland.
Rieben R; Department of Clinical Research, University of Bern, Murtenstrasse 50, P.O. Box 44, CH-3010 Bern, Switzerland. Electronic address: .
Źródło:
Biochemical pharmacology [Biochem Pharmacol] 2014 Mar 01; Vol. 88 (1), pp. 12-22. Date of Electronic Publication: 2013 Dec 30.
Typ publikacji:
Journal Article; Review
Język:
English
Imprint Name(s):
Publication: Oxford : Elsevier Science
Original Publication: Oxford, New York [etc.] Paragamon Press.
MeSH Terms:
Blood Coagulation*/drug effects
Blood Coagulation*/physiology
Complement Inactivator Proteins/*therapeutic use
Complement System Proteins/*metabolism
Reperfusion Injury/*blood
Animals ; Antibodies, Monoclonal/therapeutic use ; Clinical Trials as Topic ; Complement Inactivator Proteins/pharmacology ; Complement System Proteins/immunology ; Endothelium, Vascular/drug effects ; Endothelium, Vascular/immunology ; Endothelium, Vascular/pathology ; Humans ; Kinins/antagonists & inhibitors ; Kinins/immunology ; Reperfusion Injury/drug therapy ; Reperfusion Injury/immunology ; Reperfusion Injury/pathology ; Thromboplastin/antagonists & inhibitors ; Thromboplastin/immunology ; Treatment Outcome
Contributed Indexing:
Keywords: Complement system; Ischemia/reperfusion injury; Plasma cascade systems; Therapy
Substance Nomenclature:
0 (Antibodies, Monoclonal)
0 (Complement Inactivator Proteins)
0 (Kinins)
9007-36-7 (Complement System Proteins)
9035-58-9 (Thromboplastin)
Entry Date(s):
Date Created: 20140104 Date Completed: 20140415 Latest Revision: 20140219
Update Code:
20240104
DOI:
10.1016/j.bcp.2013.12.013
PMID:
24384116
Czasopismo naukowe
Ischemia/reperfusion injury (IRI) may occur from ischemia due to thrombotic occlusion, trauma or surgical interventions, including transplantation, with subsequent reestablishment of circulation. Time-dependent molecular and structural changes result from the deprivation of blood and oxygen in the affected tissue during ischemia. Upon restoration of blood flow a multifaceted network of plasma cascades is activated, including the complement-, coagulation-, kinin-, and fibrinolytic system, which plays a major role in the reperfusion-triggered inflammatory process. The plasma cascade systems are therefore promising therapeutic targets for attenuation of IRI. Earlier studies showed beneficial effects through inhibition of the complement system using specific complement inhibitors. However, pivotal roles in IRI are also attributed to other cascades. This raises the question, whether drugs, such as C1 esterase inhibitor, which regulate more than one cascade at a time, have a higher therapeutic potential. The present review discusses different therapeutic approaches ranging from specific complement inhibition to simultaneous inhibition of plasma cascade systems for reduction of IRI, gives an overview of the plasma cascade systems in IRI as well as highlights recent findings in this field.
(Copyright © 2013 Elsevier Inc. All rights reserved.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies